Table of Content

1. Key Insights

2. Executive Summary of PD-L1 NSCLC

3. SWOT Analysis of PD-L1 NSCLC

4. PD-L1 NSCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of PD-L1 NSCLC in 2017: By Country
4.2. Total Market Share (%) Distribution of PD-L1 NSCLC in 2030: By Country

5. PD-L1 Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Cellular Classification of NSCLC
5.1.2. Signs and Symptoms of NSCLC
5.1.3. Risk Factors of Lung Cancer
5.1.4. Causes of NSCLC
5.1.5. Disease Biology: NSCLC

6. Diagnosis of PD-L1 NSCLC
6.1. Diagnostic Algorithm for NSCLC
6.2. Stages of NSCLC
6.3. Staging System

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Total Incident cases of NSCLC patients in the 7MM
7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
7.4. The United States Epidemiology
7.4.1. Total Incident cases of NSCLC patients in the United States
7.4.2. Total Incident cases of NSCLC patients by Histology in the United States
7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
7.4.4. Total PD-L1 NSCLC cases in the United States
7.4.5. Total PD-L1 NSCLC Treated patient Pool in the United States

8. EU-5 Epidemiology
8.1. Germany
8.1.1. Total Incident cases of NSCLC patients in Germany
8.1.2. Total Incident cases of NSCLC patients by Histology in Germany
8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
8.1.4. Total PD-L1 NSCLC cases in Germany
8.1.5. Total PD-L1 NSCLC Treated patient Pool in Germany
8.2. France
8.2.1. Total Incident cases of NSCLC patients in France
8.2.2. Total Incident cases of NSCLC patients by Histology in France
8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
8.2.4. Total PD-L1 NSCLC cases in France
8.2.5. Total PD-L1 NSCLC Treated patient Pool in France
8.3. Italy
8.3.1. Total Incident cases of NSCLC patients in Italy
8.3.2. Total Incident cases of NSCLC patients by Histology in Italy
8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
8.3.4. Total PD-L1 NSCLC cases in Italy
8.3.5. Total PD-L1 NSCLC Treated patient Pool in Italy
8.4. Spain
8.4.1. Total Incident cases of NSCLC patients in Spain
8.4.2. Total Incident cases of NSCLC patients by Histology in Spain
8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
8.4.4. Total PD-L1 NSCLC cases in Spain
8.4.5. Total PD-L1 NSCLC Treated patient Pool in Spain
8.5. The United Kingdom
8.5.1. Total Incident cases of NSCLC patients in the United Kingdom
8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
8.5.4. Total PD-L1 NSCLC cases in the United Kingdom
8.5.5. Total PD-L1 NSCLC Treated patient Pool in the United Kingdom

9. Japan Epidemiology
9.1. Japan
9.1.1. Total Incident cases of NSCLC patients in Japan
9.1.2. Total Incident cases of NSCLC patients by Histology in Japan
9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
9.1.4. Total PD-L1 NSCLC cases in Japan
9.1.5. Total PD-L1 NSCLC Treated patient Pool in Japan

10. Current Treatment Practices: PD-L1 NSCLC
10.1. Advanced/Metastatic NSCLC Treatment Algorithm
10.2. Chemotherapy
10.3. Targeted Therapy
10.4. Immunotherapy
10.5. Surgery
10.6. Radiation Therapy
10.7. Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC
11.1. The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020
11.2. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
11.3. The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018
11.4. The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of PD-L1 NSCLC

13. Key Endpoints in NSCLC Clinical Trials

14. Marketed Therapies
14.1. Key Cross
14.2. Imfinzi (Durvalumab): AstraZeneca
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.2.6. Safety and Efficacy of Ongoing Clinical Trials
14.3. Opdivo (Nivolumab): Bristol-Myers Squibb
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Current Pipeline Activity
14.4. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche
14.4.1. Product Description
14.4.2. Regulatory Milestones
14.4.3. Other Developmental Activities
14.4.4. Pivotal Clinical Trials
14.4.5. Ongoing Current Pipeline Activity
14.5. Keytruda (Pembrolizumab): Merck
14.5.1. Product Description
14.5.2. Regulatory Milestones
14.5.3. Other Developmental Activities
14.5.4. Pivotal Clinical Trials
14.5.5. Ongoing Current Pipeline Activity

15. Emerging Therapies
15.1. Canakinumab (ACZ885): Novartis Pharmaceuticals
15.1.1. Product Description
15.1.2. Clinical Development
15.2. Avelumab (Bavencio): Merck KGaA and Pfizer
15.2.1. Product Description
15.2.2. Clinical Development
15.2.3. Safety and Efficacy
15.3. Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.3.1. Product Description
15.3.2. Clinical Development
15.3.3. Safety and Efficacy
15.4. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
15.4.1. Product Description
15.4.2. Clinical Development
15.4.3. Safety and Efficacy

16. PD-L1Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
16.1. Key Findings
16.2. Market Outlook: 7MM

17. PD-L1?Market Size
17.1. Total Market Size of PD-L1 NSCLC in the 7MM
17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM
17.3. United States Market Size
17.3.1. Total Market size of PD-L1 NSCLC in the United States
17.4. EU-5 Market Size
17.4.1. Germany Market Size
17.4.2. France Market Size
17.4.3. Italy Market Size
17.4.4. Spain Market Size
17.4.5. United Kingdom Market Size
17.5. Japan Market Size
17.5.1. Total Market size of PD-L1 NSCLC in Japan

18. Market Access and Reimbursement of PD-L1 NSCLC Therapies

19. Market Drivers of PD-L1 NSCLC

20. Market Barriers of PD-L1 NSCLC
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight



List of Figures


Figure 1 PD-L1 NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total Incident cases of PD-L1 NSCLC in the United States (2017–2030)
Figure 22 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25 Total Incident cases of PD-L1 NSCLC in Germany (2017–2030)
Figure 26 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29 Total Incident cases of PD-L1 NSCLC in France (2017–2030)
Figure 30 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33 Total Incident cases of PD-L1 NSCLC in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37 Total Incident cases of PD-L1 NSCLC in Spain (2017–2030)
Figure 38 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41 Total Incident cases of PD-L1 NSCLC in the United Kingdom (2017–2030)
Figure 42 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45 Total Incident cases of PD-L1 NSCLC in Japan (2017–2030)
Figure 46 Advanced/Metastatic NSCLC Treatment Algorithm
Figure 47 Timeline Illustrating the Development of Targeted Therapies and Immunotherapy’s for the Treatment of NSCLC Over two decades
Figure 48 Immune Checkpoint Inhibitor
Figure 49 Unmet Needs
Figure 50 Market Size ofPD-L1 NSCLC in the 7MM Countries, in USD Million (2017–2030)
Figure 51 Market Size of PD-L1 NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 52 Market Size ofPD-L1 NSCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 53 Market Size ofPD-L1 NSCLC in the United States by Therapies, in USD Million (2017–2030)
Figure 54 Market Size ofPD-L1 NSCLC in Germany by Therapies, in USD Millions (2017–2030)
Figure 55 Market Size ofPD-L1 NSCLC in France by Therapies, in USD Millions (2017–2030)
Figure 56 Market Size ofPD-L1 NSCLC in Italy by Therapies, in USD Millions (2017–2030)
Figure 57 Market Size ofPD-L1 NSCLC in Spain by Therapies, in USD Millions (2017–2030)
Figure 58 Market Size of PD-L1 NSCLC in the United Kingdom by Therapies, in USD Millions (2017–2030)
Figure 59 Market Size of PD-L1 NSCLC in Japan, in USD Millions (2017–2030)
Figure 60 Market Drivers
Figure 61 Market Barriers

 

List of Tables


Table 1 Summary of Non-small-cell Lung Cancer (NSCLC) Market, Epidemiology, and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States (2017–2030)
Table 10 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13 Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany (2017–2030)
Table 14 Total Incident cases of NSCLC patients in France (2017–2030)
Table 15 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17 Total NSCLC cases of patients by Genetic mutation/Biomarkers in France (2017–2030)
Table 18 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21 Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25 Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain (2017–2030)
Table 26 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29 Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom (2017–2030)
Table 30 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33 Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan (2017–2030)
Table 34 Standard Treatment Options of NSCLC (Stage-wise)
Table 35 Summary of Recommendations (SEOM Clinical Guideline)
Table 36 Strength of Evidence
Table 37 Strength of Evidence
Table 38 Marketed Drugs Key Cross
Table 39 Imfinzi (Durvalumab), Clinical Trial Description, 2020
Table 40 Opdivo (Nivolumab), Clinical Trial Description, 2020
Table 41 Tecentriq (Atezolizumab), Clinical Trial Description, 2020
Table 42 Keytruda (Pembrolizumab), Clinical Trial Description, 2020
Table 43 Canakinumab (ACZ885), Clinical Trial Description, 2020
Table 44 Avelumab, Clinical Trial Description, 2020
Table 45 Libtayo (cemiplimab) Clinical Trial Description, 2020
Table 46 M7824 (Bintrafusp alfa), Clinical Trial Description, 2020
Table 47 7MM Market Size of PD-L1 NSCLC, in USD Million (2017–2030)
Table 48 7MM Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 49 7MM Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 50 United States Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 51 United States Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 52 Germany Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 53 Germany Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 54 France Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 55 France Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 56 Italy Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 57 Italy Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 58 Spain Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 59 Spain Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 60 United Kingdom Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 61 United Kingdom Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 62 Japan Market Size of PD-L1 NSCLC By Line of Therapy, in USD Million (2017–2030)
Table 63 Japan Market Size of PD-L1 NSCLC by therapies, in USD Million (2017–2030)
Table 64 National Institute for Health and Care Excellence (NICE) Decisions for NSCLC Therapies
Table 65 IQWiG Decisions for NSCLC Therapies
Table 66 Haute Autorit? de sant? (HAS) Decisions for NSCLC Therapies